Ablexis Announce License Agreement with Novo
-
Democrats, Trump hold final rallies before midterm elections
-
African players in Europe: Defender Hakimi's historic hat-trick
-
Japan urges US to enforce discipline after second Marine arrest
-
Struggling Slavia face Arsenal as grim record looms
-
'Remarkable' rookie Lendeborg scores 37 as Warriors beat Clippers
-
Vikings suffer first loss while Broncos edge Chiefs in NFL
-
ExxonMobil urged to re-think Papua New Guinea gas project
-
South Korea to double spending on AI and chips in 2027
-
Asian stocks mixed as tech sector struggles to rebound from selloff
-
On All Saints' Day, Philippine mountain town honours dead with fire
-
India's royals find new power in their past
-
Years on from fall of IS, French jihadists face justice in Iraq
-
Irish bookshops help meet UK demand for Sally Rooney novels
-
Point of Law favourite at Australia's 'race that stops a nation'
-
NFL Vikings suffer first loss while Broncos edge Chiefs
-
'Kid' Antonelli gets affectionate tributes from all quarters
-
Host of fresh faces in Australia white-ball squads to face England
-
Hamilton accuses Leclerc of wrecking Ferrari hopes
-
NFL linebacker Campbell to remain hospitalized overnight
-
BioLargo's Clyra Medical Gains Commercial Traction as Clinician Enthusiasm Drives Health System Adoption
-
Anthony, Linder & Cacomanolis Recognized in Chambers & Partners Spotlight Florida 2027 for Securities Law Excellence
-
Palo Alto Collaboration Company Opens Waitlist for Pana, a Personal AI That Builds Tools That Stay Yours
-
cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness
-
Gladstone Commercial Corporation Earnings Call and Webcast Information
-
XCF Global Withdraws Reverse Stock Split Proposal; Reaffirms Growth Strategy and Shareholder Support
-
Vicapsys Life Sciences Provides Shareholder Update on VICAPSYN(TM) Program Advancing Toward Phase 1 Human Clinical Trial, Vertically Integrated With the Company's Indian Health Service Strategy
-
Nexscient Announces Expanded Customer Engagements and New Commercial Agreements in Autonomous Driving and Humanoid Robotics Data Services
-
Gladstone Alternative Income Fund Announces Monthly Cash Distribution for November 2026
-
Chervon Names Thomas Scherer Vice President of Organizational Development - Sales, End User Marketing, and Service
-
enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium
-
Medical Care Technologies Inc. (OTCID:MDCE) Delivers Stronger Melanoma Scan Beta Readout on Expanded Human-Submitted Dataset
-
Bank of San Francisco Reports Third Quarter 2026 Financial Results
-
Chervon Names Jody Grimsley Senior National Account Manager
-
ARC Names UptimeAI Leader in 2026 MarketMap for Industrial Copilots - Plant Operations
-
D. Boral Capital Acted as Sole Bookrunner to SPACCircle Acquisition Corp. (Nasdaq: SCQCU) in Connection with its $100,000,000 Initial Public Offering
-
International Battery Metals Announces Second Quarter Fiscal 2027 Financial Results Conference Call and Webcast
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 02
-
Aer Lingus and MTech Mobility Launch Live Ground Operations Technology Programme Across Three Irish Airports
-
DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
-
Ur-Energy Announces Retirement of CFO Roger Smith, Names VP Finance Jade Walle as Successor
-
Jaguar Mining Provides Update on Permitting of the Onças de Pitangui Development Project, Minas Gerais, Brazil
-
Hospital AI Funding Faces a Reality Check: New 2027 Outlook Puts Outsourcing Savings to the Test
-
BEING rather than HAVING. A fascinating, practical STORY.
-
Electrovaya Ranks Fourth Among Canada's Enterprise - Industry Leaders in Deloitte's Technology Fast 50(TM) Program
-
Tectonic Metals Intersects 5.61 g/t Au Over 41.15 m, Including 12.94 g/t Au Over 13.72 m, Within 2.86 g/t Au Over 91.44 m, Strengthening Evidence for a Second Gold System at the Flat Gold Project
-
iAsk.ai Surpasses One Billion Searches
-
Electric Metals (USA) Limited Announces Results of Annual Meeting of Stockholders
-
Predictiv AI Awarded Metrolinx Master Agreement for On-Demand Transit Software and Related Services
-
AsiaFIN Holdings Corp. to Host Q3 2026 Earnings Webcast from New York City
-
GameSquare to Report Q3 2026 Financial Results on November 16, 2026
Ablexis Announce License Agreement with Novo
SAN DIEGO, CA / ACCESS Newswire / October 14, 2026 / Ablexis, LLC, a biopharmaceutical company focused on advancing human antibody drug discovery through provision of its AlivaMab® Mouse technology, announced today an agreement granting Novo Nordisk A/S (Novo) a non-exclusive license to Ablexis' proprietary AlivaMab Mouse human antibody drug discovery platforms to discover, develop, and commercialize biologics drugs comprising AlivaMab antibodies. The license provides Novo rights to possess and use AlivaMab Mouse strains for the generation of human VH/VL antibodies.
"Ablexis has evolved the performance and expanded the capabilities of the AlivaMab Mouse technology since the launch of the first generation in 2014, ensuring it remains the premier technology for rapid, efficient, and successful human antibody drug discovery and development," said Larry Green, Ph.D., Chief Executive Officer of Ablexis. "Ablexis' licensees have already advanced more than 34 AlivaMab antibodies into clinical development since 2018 using the earliest versions of the technology. We are pleased that Novo selected the suite of AlivaMab Mouse strains to enhance its armamentarium for the discovery of the next generation of human biologics drugs."
The AlivaMab Mouse strains are available for use in-house by Ablexis' licensees or for service provision on a license-free, milestone-free, and royalty-free basis exclusively through AlivaMab Biologics, LLC.
About Ablexis, LLC
Ablexis, LLC creates and offers AlivaMab Mouse, a suite of unique, patented next generation transgenic mice, as a foundational platform for successful human antibody drug discovery and development. Dozens of companies, including 13 of the world's top 25 global pharmaceutical companies, public and private biotechnology companies, and other entities have licensed the AlivaMab Mouse technology for their antibody drug discovery. Ablexis' sister company, AlivaMab Biologics provides an integrated antibody therapeutic discovery and engineering platform using the AlivaMab Mouse technologies on a license-free, milestone- and royalty-free basis. For more information, please contact us at [email protected] or [email protected].
SOURCE: Ablexis, LLC
View the original press release on ACCESS Newswire
L.Harper--AMWN
